Introduction to the New RMP Framework in Japan
On September 30, 2026, Japan’s Ministry of Health, Labour and Welfare (MHLW) issued a notification outlining a revised framework for pharmaceutical Risk Management Plans (RMPs). The changes follow amendments to Japan’s Pharmaceuticals and Medical Devices Act (PMD Act) and related regulations and will take effect on May 20, 2027.
The key change is that RMP requirements will no longer rely primarily on conditions attached to individual marketing authorizations. Instead, when necessary to ensure the safety and effectiveness of a medicinal product, marketing authorization holders (MAHs) will have a statutory obligation to prepare an RMP, report its creation and modification, and implement risk management activities in accordance with the plan.
From an Approval Condition to a Statutory Obligation
Under the previous framework, preparation and implementation of an RMP were generally required through conditions attached to the marketing authorization, and whether the RMP could be terminated was typically considered at the time of re-examination.
Under the revised framework, termination will require an affirmative, evidence-based determination by the MAH and reporting to PMDA, rather than occurring as an implicit consequence of re-examination.
Under the revised framework, the RMP becomes a more dynamic, lifecycle-based regulatory requirement. An RMP may be required whenever MHLW considers it necessary to ensure the safety and effectiveness of a medicinal product, including when a new safety concern emerges after approval.
This change provides the Japanese authorities with a mechanism to respond more rapidly to emerging safety concerns according to the characteristics and significance of the identified risk.
When an RMP Will Be Required
The revised framework applies to prescription medicinal products, excluding in vitro diagnostics. The need to prepare an RMP must be considered at several important points in the product lifecycle, including:
An RMP will be required when additional pharmacovigilance activities or additional risk-minimization activities are considered necessary, or when specific safety/effectiveness investigations or studies are required.
Additional Pharmacovigilance Activities
An RMP may be required when routine pharmacovigilance activities alone are insufficient and additional planned collection of safety information is necessary based on the characteristics of the product and its identified or potential risks.
The framework therefore distinguishes routine pharmacovigilance from additional pharmacovigilance activities, allowing monitoring strategies to be tailored to the specific safety profile of each product.
Additional Risk-Minimization Activities
Similarly, an RMP may be required when routine risk-minimization measures are not considered sufficient to maintain an appropriate benefit-risk balance. In such cases, additional measures tailored to the characteristics and risks of the product may be necessary.
The framework also covers activities designed to collect information relating to specific events or patient populations, including certain safety information collection for biosimilars, as well as investigations or studies relating to effectiveness.
RMP Reporting Requirements
Under the new statutory framework, RMP-related reports to the Minister of Health, Labour and Welfare will be submitted through the Pharmaceuticals and Medical Devices Agency (PMDA).
MAHs will be required to report promptly to PMDA when:
Results from safety and effectiveness information collection activities, their evaluation, and any resulting measures must also be reported according to the timelines specified in the RMP.
Responding to New Safety Signals After Approval
An important feature of the revised framework is its emphasis on continuous lifecycle risk management.
If a new safety concern emerges after an RMP has been established, the MAH should promptly consider whether the existing RMP needs to be modified and should consult with PMDA before making the change.
Importantly, this concept also applies to products without a current RMP. If a new safety concern emerges for a product that has never had an RMP, or whose RMP has already been terminated, the MAH should promptly consider establishing a new RMP and consult PMDA in advance.
Importance of Cross-Functional Planning During Development
Although RMPs primarily address post-marketing risk management, MHLW emphasizes that benefit-risk assessment and planning for appropriate safety measures should begin during drug development and continue through regulatory review.
The notification specifically highlights the need for collaboration between the organization responsible for post-marketing safety management and the functions responsible for drug development when preparing the RMP.
For global pharmaceutical companies, this reinforces the importance of integrating Japan-specific pharmacovigilance and risk-management considerations into regulatory strategy before approval, rather than addressing the Japanese RMP only at the final stage of the filing process.
Effective Date and Transitional Measures
The revised statutory RMP requirements will become effective on May 20, 2027.
For products that already have an RMP requirement imposed as a condition of approval on that date, the existing framework will continue to apply until the relevant approval condition is removed.
For products approved after the effective date, the new statutory framework will apply where an RMP is required. MHLW also indicates that transitional arrangements will be established regarding the content and preparation of RMPs, with further details to be provided separately.
Practical Implications for Global Pharmaceutical Companies
For non-Japanese pharmaceutical companies planning development or commercialization in Japan, the revision represents an important change in the positioning of RMPs.
The key practical implications are:
Conclusion
Japan’s revised RMP framework represents an important shift from an approval-condition-based model toward a statutory, lifecycle-oriented risk management system. Effective May 20, 2027, pharmaceutical companies may be legally required to establish, modify, report and implement RMPs whenever necessary to ensure the continued safety and effectiveness of their products.
For global pharmaceutical companies, the practical message is clear: Japan RMP strategy should increasingly be viewed as a lifecycle responsibility rather than simply a post-approval commitment established at the time of marketing authorization. Early coordination among regulatory, development and pharmacovigilance functions will therefore become increasingly important for successful product development and lifecycle management in Japan.
Reference